Weight-loss drug lowers cardiovascular disease risk in new trial of Novo Nordisk's Wegovy

Nat Med. 2023 Oct;29(10):2381-2382. doi: 10.1038/d41591-023-00075-x.
No abstract available

Publication types

  • News

MeSH terms

  • Anti-Obesity Agents* / therapeutic use
  • Cardiovascular Diseases* / drug therapy
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / prevention & control
  • Diabetes Mellitus, Type 2*
  • Humans
  • Risk Factors

Substances

  • Anti-Obesity Agents